• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Johns Hopkins Rheumatology

Show Search
Hide Search
  • About Us
    • Our History
    • Our Faculty
    • Rheumatology Fellowship
    • Administrative Core
    • Contact Us
    • eNews Signup
  • Make an Appointment
    • Clinic Information
    • Specialty Clinics
  • Our Research
    • Current Research Studies
    • Andrade Lab
    • Darrah Lab
    • Konig Lab
    • Rosen Casciola Lab
    • RDRCC
    • Bayview Immunomics Core (BIC)
  • Charitable Giving
    • Dr. John Welton Fellowship in Rheumatology
    • Dr. Ira T. Fine Discovery Fund
    • Dr. Nadia D. Morgan Memorial Fund
  • News
    • LEAP Magazine
  • Education
    • Advances in the Diagnosis and Treatment of the Rheumatic Diseases Course
    • RheumTV – Patient Education Video Library
Home / News / Research / Smoking is Not to Blame for PAD4 Antibody Development in Patients with RA

Smoking is Not to Blame for PAD4 Antibody Development in Patients with RA

March 26, 2018 By Erika Darrah

A history of cigarette smoking is linked to the development of rheumatoid arthritis (RA) and specific immune responses to proteins within the body. However, a team of researchers from the Johns Hopkins Division of Rheumatology studying patients seen at Arthritis Center, found that smoking was not the driving force behind the generation of antibodies that bind to an enzyme called PAD4. This suggests that environmental factors other than smoking are responsible for the generation of these antibodies in patients with RA. Since patients with antibodies to PAD4 have the most severe joint and lung disease, understanding the environmental risk factors that lead to their development could lead to strategies to prevent their generation in the future.

Why was this study done?

A combination of genetic and environmental factors is thought to be responsible for the development RA. In particular, a history of cigarette smoking has been most strongly linked to the development of this inflammatory joint disease, as well as resulting immune responses to citrullinated proteins. These immune responses are detected in the clinic by the anti-CCP assay. Citrullinated proteins are generated by an enzyme called PAD4, and some patients with RA also make antibodies to the PAD4 enzyme . However, it was unknown if smoking was responsible for the development of antibodies to this important enzyme. This study was done to understand if a history of cigarette smoking was linked to the development of antibodies to PAD4 in patients with RA.

How was this study done?

The research team studied 274 people with RA seen at the Johns Hopkins Arthritis Center who agreed to participate in this study. Study participants had routine clinical exams, completed a questionnaire that collected information about their smoking history, and donated blood for PAD4 antibody testing. These data were then analyzed by the research team to identify factors, including smoking history, that may be linked to the development of PAD4 antibodies in patients with RA.

What were the major findings?

In this group of patients, PAD4 antibodies were found more commonly individuals who had RA for a long period time, an average of 15.5 years. These individuals were also more likely to have specific genetic features called the “HLA shared epitope”, test positive for anti-CCP antibodies, and have evidence of more joint damage on X-ray. When the participants were asked about their smoking history, researchers found that a history of ever smoking was not linked to the development of PAD4 antibodies. In fact, current smokers were less likely to develop PAD4 antibodies than people who did not actively smoke at the time of the study.

What is the impact of this work?

Although smoking is linked to several severe health problems, including the development of RA, it does not appear to be the driving factor for the development of PAD4 antibodies in patients with RA. It is important to understand why people develop RA and generate specific immune responses to self proteins, like PAD4. If smoking is not the responsible driving factor, it is important to explore other environmental triggers that might lead to the development of these antibodies found in patients with the most severe RA. Other possible culprits include infections, including infections of the gums, which have recently been linked to RA development. Identifying modifiable environmental triggers of RA and resulting immune responses could lead to preventative strategies to one day stop their development.

This research was supported by:

Office of the Assistant Secretary of Defense for Health Affairs through the Peer Reviewed Medical Research Program under Award No. W81XWH-15-1-0159, and the Camille Julia Morgan Arthritis Research and Education Fund.

Link to original research article:

Smoking is not linked to the development of anti-peptidylarginine deiminase 4 autoantibodies in rheumatoid arthritis
Laura C. Cappelli†, Maximilian F. Konig†, Allan C. Gelber, Clifton O. BinghamIII and Erika Darrah †Contributed equally.
Arthritis Research & Therapy201820:59

Receive the Latest News from Johns Hopkins Rheumatology

Receive the Latest News from Johns Hopkins Rheumatology

Join our mailing list to receive the latest news and updates from Johns Hopkins Rheumatology.

Interested In

You have Successfully Subscribed!

Filed Under: Research Tagged With: RA, Rheumatoid Arthritis

Erika Darrah

Erika Darrah, Ph.D. is an Assistant Professor of Medicine in the Johns Hopkins University Division of Rheumatology with an interest understanding the mechanisms that drive the development of rheumatic diseases.

Use of this Site

All information contained within the Johns Hopkins Division of Rheumatology website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.

Primary Sidebar

Rheumatology News

  • News
  • Promotions

Recent News

LEAP – Winter 2023: Big Data, Individualized Care

February 23, 2023

LEAP Rounds – Holiday 2022

November 9, 2022

Dr. Rachel Wallwork named ACR Distinguished Fellow

October 19, 2022

RheumTV Logo

Rheum.TV is an educational platform created to help patients living with a rheumatic disease. With over 100 disease education videos produced by the team at Johns Hopkins Rheumatology.

Visit RheumTV

Footer

Rheumatology Specialty Care Centers

  • Johns Hopkins Arthritis Center
  • Johns Hopkins Lupus Center
  • Johns Hopkins Lyme Disease Research Center
  • Johns Hopkins Myositis Center
  • Johns Hopkins Scleroderma Center
  • Johns Hopkins Sjögren’s Syndrome Center
  • Johns Hopkins Vasculitis Center

Connect with Us

  • Facebook
  • Twitter
  • YouTube
U.S. News and World Report Rankings Badge

Johns Hopkins Medicine

© 2023 Johns Hopkins Rheumatology - Patient Privacy